[Treatment of high malignancy lymphoma with intensive short-term chemotherapy using the MACOP-B regimen].

Abstract

We present our results of a MACOP-B regimen in a series of 46 patients with high-grade NHL. The complete remission rate was 74% for patients with advanced stage disease. The excellent tolerance allowed this regimen to be given on an outpatient basis in the majority of cases. The median follow-up for the living patients is 28 months. Although some patients received additional treatment that could influence the results, the predicted DFS (disease-free survival) at 45 months of 57% compares favorably with the best results published so far with more toxic regimens.

• Authors: A Delmer, F Bauduer, A Ruskoné-Fourmestraux, F Ajchenbaum-Cymbalista, B Delmas-Marsalet, B Rio, J P Marie, R Zittoun
• Journal: Bulletin du cancer (Bull Cancer) Vol. 80 Issue 9 Pg. 808-15 (Sep 1993) ISSN: 0007-4551 [Print] France
• Vernacular Title: Traitement des lymphomes de grande malignité par chimiothérapie courte et intensive de type MACOP-B.
• PMID: 7515735 (Publication Type: English Abstract, Journal Article)

Chemical References

• Bleomycin
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisolone
• Methotrexate

Topics

• Adult
• Aged
• Ambulatory Care
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bleomycin (therapeutic use)
• Cyclophosphamide (therapeutic use)
• Doxorubicin (therapeutic use)
• Drug Tolerance
• Female
• Humans
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Methotrexate (therapeutic use)
• Middle Aged
• Prednisolone (therapeutic use)
• Prospective Studies
• Survival Rate
• Treatment Outcome
• Vincristine (therapeutic use)